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Professor Zwiggelaar, could you provide 
a brief outline of your research career? 
How did you first become involved in 
computer science?
My PhD was related to optical signal processing 
and, during my first postdoctoral position at 
the Silsoe Research Institute, UK, I switched 
to computer-based signal/image processing, 
with some applications in the clinical domain. 
During my second postdoctoral position 
at the University of Manchester, I worked 
exclusively on medical image analysis, mainly 
mammography. During subsequent faculty 
positions at the University of Portsmouth 
and the University of East Anglia, I developed 
broader medical image analysis and computer 
vision work across a range of application areas. 
In the medical domain this covered breast, 
prostate, lung and brain cancers, and analysis of 
associated images (radiology, blood, cells), while 
in other areas this covered the analysis of plants, 
crops, faces, biometrics and chronic obstructive 
pulmonary disease. I am currently a professor 
at the Department of Computer Science at 
Aberystwyth University.
How can the effectiveness of cancer 
screening be increased using computer-aided 
diagnosis (CAD) prompting systems? 
There are a number of aspects where 
contributions are made. Most of the time, 
prompting systems are used as a second opinion 
and, in effect, contribute to the early detection 
of abnormalities; sometimes early signs are 
missed or deemed normal, in which case a 
prompt might alert the clinical expert. The same 
could happen when the CAD system does not 
indicate an area where the expert was suspecting 
something. The second way in which a CAD 
system can contribute is in the classification 
of an abnormality as malignant, which is likely 
to affect the number of biopsies taken and the 
direct effect this has on the patient.
How do you develop the methodology for 
statistical models? What are the benefits 
of using a model-based approach in 
your research?
Statistical modelling relies on the distinction 
between abnormal and normal regions, and 
in having enough examples of all the different 
classes. In effect, the methodology involves 
obtaining a model based on a distinct set of 
examples. If the models are specific enough, 
they can be used to distinguish between 
unseen cases. 
The biggest benefit of such model-based 
approaches is that the results tend to be within 
the anatomical expected variations and are 
realistic. Modelling can be restricted to cover 
only a limited range of variation from the 
training data. It also provides a probabilistic 
approach that makes classification easier, 
and can be used to generate examples, 
that are realistic and can teach us about 
cancer development.
What are the biggest challenges involved in 
evaluating and improving the understanding 
and assessment of medical images?
The evaluation tends to involve large numbers 
of cases, which are similar to clinical trials. In 
many of the application areas we work in, one 
of the biggest problems is obtaining reliable 
ground truth data at a detailed enough level. For 
example, we might know that there is cancer in a 
prostate, but be unsure of its precise location and 
rely on experts to outline the relevant region.
How important is collaboration to your line 
of research? 
It is essential, especially with clinical experts. 
Professor Erika Denton from the University of 
East Anglia is a longstanding collaborator with 
whom we have been working for almost 15 years. 
She provides ground truth data for creating 
models, is involved in design discussions and 
plays a major role in evaluation aspects.
From a computer science point of view, we 
collaborate both within Aberystwyth and 
abroad; the University of Girona, Spain, and 
the University of Pennsylvania, USA, are 
longstanding collaborators.
How do you see your research developing in 
the future?
There always seems to be room for improvement. 
In breast cancer for example, computer-aided 
detection is getting close to the performance 
of clinical experts, but the classification is an 
area where significant improvements can be 
made. Classification could try to investigate links 
between complex appearance and biopsy data.
This research has the potential to develop 
towards applications, especially in the 
classification of mammographic and prostate 
abnormalities, mammographic risk assessment 
and the analysis of blood and cell images. Our 
research tends to be an interaction between 
basic research, specific application areas and 
translation to clinical end-users.
Professors Reyer Zwiggelaar and Erika Denton, and Dr Harry Strange are creating 
groundbreaking new models of cancer risk. Here, they discuss the challenges they face and the 
collaborations they participate in that contribute to the constant improvement of their work
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OVER 25 MILLION people around the world 
are living with cancer, with more than 11 million 
new diagnoses every year. Catching cancer early 
can signifi cantly improve a patient’s chance of 
survival as the tumours are smaller, less likely to 
have spread and therefore easier to treat. 
Cancers are mostly detected by physicians using 
imaging techniques such as magnetic resonance 
imaging (MRI), X-rays or ultrasound. The results 
can often be diffi cult to interpret, partly due to 
the natural variation in patients and because 
individual physicians will read the images 
slightly differently using subjective criteria, 
leading to both false negative and false positive 
outcomes. To address this problem, Professor 
Reyer Zwiggelaar from Aberystwyth University, 
UK, is working alongside his colleague Dr 
Harry Strange and collaborator, Professor Erika 
Denton, from Norfolk and Norwich University 
Hospital. Together, they have developed a set of 
promising new computer-aided diagnosis tools 
that could revolutionise the detection of a range 
of cancers, including breast, brain and prostate. 
HIGHLIGHTING BREAST CANCER RISK
Each year, over 2 million women in the UK are 
screened for breast cancer using a mammogram, 
with around 16,500 tumours detected. As the 
risk of breast cancer is strongly linked to age, 
all women between the ages of 50 and 70 are 
invited for screening every three years. Physicians 
can recommend more frequent screening when 
an individual has a higher risk of disease, which is 
currently determined based on their lifestyle and 
family history. At present, Zwiggelaar’s research 
is working towards an improved understanding 
of a variety of biological and clinical risk factors 
within an individual’s breast tissue that could 
better inform the risk assessment process.
Breast tissue density is known to be an important 
risk factor for cancer; individuals with denser 
breast tissue are up to fi ve times more likely 
to develop a tumour, and the mammogram 
screen is less likely to discover an abnormality 
because the surrounding dense tissue obscures 
its detection. The distribution of dense 
fi broglandular tissue is therefore important for 
assessing cancer risk. The effectiveness of using 
these factors in risk assessments, however, is 
limited by the variation between physicians in 
their classifi cation of the density and distribution 
of the fi broglandular tissue, as different observers 
will have different opinions of what constitutes 
‘dense’. To address this issue, Zwiggelaar and his 
team have developed automated image analysis 
software that eliminates observer variability and 
highlights patients who are more at risk.
AUTOMATED ABNORMALITY DETECTION
Closely related is the detection of mammographic 
abnormalities. “We aimed to model the normal 
representation of the breast and detect any 
deviation from that as the probability of 
abnormality,” explains Zwiggelaar. He created 
a computer model that automatically processes 
mammogram images, calculating the density, 
segmentation and textures of the tissues, which 
enables the identifi cation of abnormalities 
Automated image analysis means 
all patients are subject to the same 
criteria for cancer risk
Computer-aided 
diagnosis
Cancer diagnosis based on imaging is subject to variability in 
the observer’s defi nition of health. Research at Aberystwyth 
University, UK, has produced an array of computer-aided diagnostic 
tools to aid the understanding of medical images
Anatomical tissue segmentation results to indicate 
mammographic density and risk.
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Topographic-based breast density segmentation.
associated with breast cancer. “We developed 
this approach based on a technique borrowed 
from facial analysis, which exploits the variation 
in the shape and contrast of masses across 
a large dataset,” elaborates Zwiggelaar. This 
automated image analysis means all patients 
are subjected to the same criteria for breast 
cancer risk, providing the physician with an 
objective second opinion that could prevent the 
unnecessary worry of a false positive diagnosis or 
a potentially life-threatening false negative.
Mammographic images are very useful but 
are only able to provide a projection image of 
the 3D breast structure. An alternative screen 
called tomosynthesis overcomes this issue 
by subjecting the patient to several small 
X-rays at different orientations to build up a 
3D representation of the breast tissue. This 
affords the observer access to, and therefore a 
deeper understanding of, the anatomical tissue 
structures. One such feature are linear structures 
which, while they can represent normal tissue 
architecture such as milk ducts or blood vessels, 
can also reveal abnormal structures. “Spiculated 
lesions tend to be malignant and have a distinct 
pattern of radiating linear structures associated 
with them,” reveals Zwiggelaar. “There can also 
be a central mass-like structure.” It is diffi cult 
to tell using a mammogram whether or not 
the linear structures are spiculated lesions, 
so Zwiggelaar and his team have created 
computer-aided diagnosis models using 3D 
tomosynthesis to reveal their true structure: 
“Our techniques are capable of detecting the 
location and orientation of linear structures, 
and also provide an indication of the associated 
anatomical structures in a cross-section,” he 
enthuses. This will help physicians to distinguish 
between normal and abnormal linear structures.
TARGETING PROSTATE CANCER BIOPSIES
Around 40,000 men in the UK are diagnosed 
with prostate cancer every year, which is 
predicted to become the UK’s most common 
cancer by 2030. Rectal exams are often used to 
detect tumours in combination with assessing 
the amount of prostate-specifi c antigen in the 
blood, which increases when the prostate is 
inﬂ amed or has cancer. Imaging techniques such 
as transrectal ultrasound and MRI can be used 
to evaluate a tumour’s volume and invasiveness 
into neighbouring tissues, identifying patients 
at an advanced stage of cancer. Interobserver 
variation is a problem with the use of these 
imaging methods, which has led Zwiggelaar 
to spend several years developing computer-
aided diagnostic tools for prostate cancer that 
can determine tissue segmentation and tumour 
confi nement in the organ.
One of his team’s most recent efforts was to 
improve the targeting of biopsies performed to 
assess the invasiveness of a tumour. Typically, 
biopsied tissue is taken from the prostate at 
random locations; however, this approach 
can miss the cancerous tissue, leading to an 
underestimate of tumour aggression and 
disease severity in half of all cases. Zwiggelaar’s 
group designed a computer-aided diagnostic 
tool aimed at the prostate peripheral zone, 
from which 80-85 per cent of prostate cancers 
arise. The tool divides the MRI images of the 
peripheral zone into four subregions and uses 
the difference in greyscale and contrast to 
determine the most cancerous of the sections. 
This technique can be used to perform fewer 
and more accurately targeted biopsies for the 
patient and obtain a better understanding of 
their cancer.
BLOOD INDICATORS OF BRAIN CANCER
Glioblastoma multiforme is the most aggressive 
type of brain cancer and can be very diffi cult 
to remove safely. Tumours require their own 
blood supply to grow and Zwiggelaar has 
identifi ed tumour vasculature as a promising 
method of assessing their biological features. 
The researchers used stable xenon computed 
tomography (CT) to investigate the vasculature 
of glioblastomas. The patient undergoes a CT 
scan whilst simultaneously inhaling xenon gas 
– the amount of xenon diffusing into the brain 
correlates to blood ﬂ ow. The image is processed 
into a blood ﬂ ow map, for which Zwiggelaar has 
developed a method to assess two important 
biological features; neurological necrosis 
and vascularity. In glioblastomas, tumour 
vasculature is not able to give adequate tissue 
perfusion, so a reduced blood ﬂ ow is indicative 
of a higher level of cancer angiogenesis. It 
is also possible to determine the amount of 
neurological tissue still remaining within the 
tumour, if any, which is vital for a preoperative 
assessment of the maximum amount of tumour 
that is safe to remove without damaging healthy 
brain tissue.
CONTINUOUS IMPROVEMENT
The contributions that Zwiggelaar has made 
to the fi eld of automated medical imaging 
analysis are indicative of his constant drive to 
improve. The computer-aided diagnostic tools 
he has already developed have a high degree of 
accuracy, but he is keen to ensure that they are 
useful in a clinical setting to guide cancer risk 
assessments, diagnosis and classifi cation in an 
objective and precise way in the future.
IMAGING TECHNIQUES FOR IMPROVED 
DIAGNOSIS FOR BREAST, BRAIN, 
BLOOD AND PROSTATE CANCER 
OBJECTIVES
To assist radiologists (and other clinical 
experts) in their understanding and 
assessment of medical images by using 
advanced computer modelling techniques.
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REYER ZWIGGELAAR received the Ir. 
Degree in Applied Physics from the State 
University Groningen, Netherlands, in 1989, 
and his PhD in Electronic and Electrical 
Engineering from University College London, 
UK, in 1993. He is currently Professor at 
the Department of Computer Science, 
Aberystwyth University, UK, and the author 
or co-author of more than 200 conference 
and journal papers. Zwiggelaar’s current 
research interests include medical image 
understanding, particularly focusing on 
mammographic and prostate data, pattern 
recognition, statistical methods, topological 
data analysis, texture-based segmentation 
and feature-detection techniques.
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